X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

X4 Pharmaceuticals reports positive trial results and financial resilience

X4 Pharmaceuticals showcased strong clinical performance with positive trial results for mavorixafor, while also strengthening its financial position despite reporting a net loss.
The company faces challenges in managing R&D expenses and addressing ongoing financial losses, but opportunities lie in market expansion and regulatory progress for mavorixafor.
By navigating challenges effectively and capitalizing on opportunities, X4 Pharmaceuticals can position itself for growth and success in advancing its lead candidate to market.
Investor interest, regulatory milestones, and strategic partnerships will play key roles in shaping X4 Pharmaceuticals' future trajectory and market competitiveness.

X4 Pharmaceuticals reports successful Phase III trial and plans FDA filing

X4 Pharmaceuticals demonstrated significant progress with mavorixafor and plans for regulatory filings, supported by a healthy cash position.
While facing challenges in managing expenses and achieving profitability, the company remains focused on advancing its pipeline and engaging with stakeholders.
Opportunities lie in upcoming events for collaboration and data dissemination, signaling potential growth avenues for X4 Pharmaceuticals.
Overall, X4 Pharmaceuticals' Q1 2023 earnings call highlighted achievements, financial standing, challenges, and future prospects for investors and stakeholders.

X4 Pharmaceuticals reports strong Q2 results and advances mavorixafor trials

X4 Pharmaceuticals showcased positive trial results and financial strength, positioning the company for future growth and market success.
While facing challenges in upcoming trials and commercialization, the company's strategic leadership and product potential offer opportunities for expansion.
Navigating regulatory processes and market dynamics will be key to realizing the full potential of mavorixafor and driving long-term value for stakeholders.
Overall, X4 Pharmaceuticals' focus on innovation, strategic partnerships, and market insights bode well for their competitive positioning and growth trajectory.

X4 Pharmaceuticals poised for mavorixafor launch in 2024

X4 Pharmaceuticals is on track for a significant mavorixafor launch in 2024, backed by strong financials and strategic initiatives. Challenges in patient diagnosis and access require focused efforts post-approval.

X4 Pharmaceuticals reports milestone achievements and financial stability for growth

X4 Pharmaceuticals showcased strong clinical advancements and financial stability in 2023, positioning them for potential FDA approval and market expansion.
While facing challenges in managing expenses and addressing stakeholder queries, the company remains optimistic about revenue opportunities and growth prospects.
With a focus on regulatory milestones, market entry strategies, and revenue generation, X4 Pharmaceuticals aims to capitalize on the momentum from their achievements.

X4 Pharmaceuticals reports FDA approval for XOLREMDI, faces financial challenges

X4 Pharmaceuticals faces financial challenges with a significant net loss despite having a substantial cash position.
The FDA approval of XOLREMDI for WHIM syndrome highlights the company's progress in drug development.
Opportunities lie in expanding XOLREMDI's market reach, monetizing PRV, and advancing R&D efforts for future growth.

X4 Pharmaceuticals excels in Phase II study and FDA approval, eyes market expansion in 2025

X4 Pharmaceuticals showcased positive results from the Phase II study of mavorixafor and FDA approval for XOLREMDI, signaling significant advancements in product development and market penetration.
While challenges exist in transitioning to Phase III trials and ensuring successful commercialization, the company's focus on physician comfort, disease awareness, and patient education presents opportunities for growth.
Overall, X4 Pharmaceuticals is well-positioned to capitalize on its recent achievements and drive further success through strategic initiatives in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Company now focused on advancing lead clinical candidate mavorixafor in  chronic neutropenic disorders, including WHIM syndrome

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase an aggregate of 50,925,365 shares of common stock, to certain institutional accredited investors in a private investment in public equity (PIPE) financing. X4 anticipates that gross proceeds from the PIPE will be approximately $55 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The closing of the financing is expected to occur on or about July 6, 2022, subject to customary closing conditions.

X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it will present research data supporting the mechanism and market potential of its lead drug candidate, mavorixafor, as part of three posters at the upcoming European Hematology Association (EHA) congress to be held in Vienna, Austria, June 9-17, 2022.

X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Schulman - Vice President, Investor Relations and Corporate Communications Paula Ragan - President and Chief Executive Officer Adam Mostafa - Chief Financial Officer Diego Cadavid - Chief Medical Officer Arthur Taveras - Chief Scientific Officer Conference Call Participants Marc Frahm - Cowen & Company William Wood - B. Riley Securities Trevor Howard - Oppenheimer Zegbeh Jallah - ROTH Capital Partners Operator Greetings and welcome to X4 Pharmaceuticals First Quarter 2022 Financial and Operating Results Conference Call.

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2022 Results - Earnings Call Transcript

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22

X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will report its financial results for the first quarter ended March 31, 2022, and provide an update on recent business highlights, on May 12, 2022.

X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will present a poster on its Waldenström's macroglobulinemia program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, LA April 8-12, 2022.

X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 and participate in a fireside chat at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference on Thursday, April 14, 2022.

X4 Pharmaceuticals to Present at April Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call Transcript

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome  expected in 4Q22

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the fourth quarter ended December 31, 2021, and provide an update on recent business highlights, on March 17, 2022.

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will participate in a panel at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 and in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022.

X4 Pharmaceuticals to Present at March Investor Conferences

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022.

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

Energy Focus

Qualigen Therapeutics

ReTo Eco-Solutions

Society Pass

Penny stocks to watch after Society Pass (NASDAQ: SOPA) skyrockets in December. The post Low Float Penny Stocks To Watch After SOPA Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Low Float Penny Stocks To Watch After SOPA Stock Explodes

Bellerophon Therapeutics

Genfit - ADR

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Biotech Penny Stocks Exploded Today, Here's Why

X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares are trading lower despite releasing what it described as positive phase 2 data for mavorixafor for WHIM syndrome, a rare congenital immune deficiency. In a poster presentation at the American Society of Hematology Annual Meeting, treatment with mavorixafor led to increases in neutrophils, lymphocytes, and monocytes and sustained improvements in infections and warts ongoing Phase 2 open-label extension trial.

Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?

- Presented data highlight mavorixafor's ability to raise the spectrum of white blood cell counts across a broad range of diseases with or without CXCR4 mutations  including Chronic Neutropenia -

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Alzamend Neuro

Cellectar BioSciences

Mustang Bio

ReShape Lifesciences

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

- CXCR4 antagonism proof of concept established, with 100% overall response rate  to combination treatment in frontline and refractory patients -

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström's Macroglobulinemia

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at Stifel's Virtual Healthcare Conference on Wednesday, November 17, 2021.

X4 Pharmaceuticals to Participate in Stifel's Virtual Healthcare Conference

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2021 Results - Earnings Call Transcript

Data continue to support mavorixafor's potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström's macroglobulinemia

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting Earnings Call taking place at 9:05 a.m. ET expected to include discussion of abstracts accepted to the upcoming 63rd American Society of Hematology (ASH) Annual Meeting

News for X4 Pharmaceuticals Inc Stock (XFOR)